NEW YORK, February 1, 2017 /PRNewswire/ --
This morning, Stock-Callers.com scans the performances of select equities in the Medical Appliances and Equipment space,
namely: EnteroMedics Inc. (NASDAQ: ETRM), Abbott Laboratories (NYSE: ABT), Boston Scientific Corp. (NYSE: BSX), and Medtronic PLC
(NYSE: MDT). These stocks belong to the Healthcare sector which closed mostly higher on Tuesday, January
31st, 2017, after the White House promised less regulation and more competition for drugmakers at a meeting
with industry executives. As per a NASDAQ report, the NYSE Health Care Index added 1.0% in value, while shares of health care
companies in the S&P 500 stretched out to a 1.4% gain as a group. Download the free research reports on these stocks
today:
http://stock-callers.com/registration
EnteroMedics
St. Paul, Minnesota headquartered EnteroMedics Inc.'s shares saw a decline of 3.53%,
finishing Tuesday's trading session at $6.29. A total volume of 1.27 million shares was traded. The
stock has surged 157.79% in the past month, 6,344.67% over the previous three months, and 214.50% since the start of this year.
The Company's shares are trading above their 50-day and 200-day moving averages by 69.02% and 435.87%, respectively. Moreover,
shares of EnteroMedics, which focuses on the design and development of devices that use neuroblocking technology to treat
obesity, metabolic diseases, and other gastrointestinal disorders, have a Relative Strength Index (RSI) of 48.77.
On January 23rd, 2017, EnteroMedics announced the closing of an underwritten public
offering of units for gross proceeds of $19.0 million. The offering comprised of Class A units,
priced at a public offering price of $5.31 per unit, with each unit consisting of one share of
common stock and one five-year warrant to purchase one share of common stock with an exercise price of $5.84 per share, and Class B Units, priced at a public offering price of $1,000
per unit, with each unit comprised of one share of preferred stock, which is convertible into 188 shares of common stock, and
warrants to purchase 188 shares of common stock. See our free and comprehensive research report on ETRM at:
http://stock-callers.com/registration/?symbol=ETRM
Abbott Laboratories
On Tuesday, shares in Abbott Park, Illinois headquartered Abbott Laboratories recorded a
trading volume of 12.32 million shares, which was above their three months average volume of 9.13 million shares. The stock ended
the session 1.85% higher at $41.77. The Company's shares have gained 9.74% in the last one month,
6.32% in the previous three months, and 9.45% on an YTD basis. The stock is trading 6.51% above its 50-day moving average and
3.96% above its 200-day moving average. Furthermore, shares of Abbott Laboratories, which manufactures and sells health care
products worldwide, have an RSI of 75.29.
On January 25th, 2017, Alere Inc. announced that the European Commission has granted
clearance for Abbott Laboratories to acquire Alere. On February 01st, 2016, Alere has
entered into a definitive agreement under which Abbott will acquire Alere for $56 per common share
in cash.
On January 26th, 2017, research firm RBC Capital Markets reiterated its 'Outperform'
rating on the Company's stock with a decrease of the target price from $48 a share to $46 a share. ABT free research report PDF is just a click away at:
http://stock-callers.com/registration/?symbol=ABT
Boston Scientific
Shares in Marlborough, Massachusetts headquartered Boston Scientific Corp. closed at
$24.06, climbing 0.88% from the last trading session. The stock recorded a trading volume of 6.52
million shares. The Company's shares have advanced 10.88% in the last one month, 8.92% over the previous three months, and 11.23%
on an YTD basis. The stock is trading 9.58% and 6.11% above its 50-day and 200-day moving averages, respectively. Additionally,
shares of Boston Scientific, which develops, manufactures, and markets medical devices for use in various interventional medical
specialties worldwide, have an RSI of 73.30.
On January 03rd, 2017, Boston Scientific announced that it will webcast its
conference call discussing financial results for Q4 2016 on February 02nd, 2017, at
8:00 a.m. ET. The Company will issue a news release announcing financial results on February 02nd, 2017, prior to the conference call. Sign up for your complimentary report on BSX
at:
http://stock-callers.com/registration/?symbol=BSX
Medtronic
At the closing bell yesterday, shares in Dublin, Ireland headquartered Medtronic PLC ended
1.81% higher at $76.02. A total volume of 7.81 million shares was traded, which was above their
three months average volume of 7.04 million shares. The stock has advanced 6.26% in the last one month and 6.72% since the start
of this year. The Company's shares are trading above their 50-day moving average by 3.12%. Furthermore, shares of Medtronic,
which manufactures and sells device-based medical therapies worldwide, have an RSI of 63.39.
On January 03rd, 2017, research firm Morgan Stanley downgraded the Company's stock
rating from 'Overweight' to 'Equal-Weight', with a target price of $77 per share. Register for free
on Stock-Callers.com and download the latest research report on MDT at:
http://stock-callers.com/registration/?symbol=MDT
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a
third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on
analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed
any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently
reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or
interfere in the application of such procedures by the third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or
the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing
of the information, or (2) warrant any results from use of the information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities
mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers
in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a
company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA